Pharmasyntez, a group of companies, has successfully made its inaugural delivery of cutting-edge anticancer medications for the treatment of breast and prostate cancer to the Dominican Republic. Pharmasyntez-Nord’s drug production site achieved successful drug registration in 2022.
“Cooperation with the Dominican Republic began in 2019. At that time, prices for anticancer drugs in the country were quite high, and the possibilities of competition with local importers were obvious to us. Thanks to the successful implementation of drug supply plans, patients in the Dominican Republic will now have increased access to crucial antitumor medications. Pharmasintez is the first exporter of Russian anticancer drugs to the Dominican Republic, so we plan to occupy a worthy niche in this segment and continue long-term fruitful cooperation with the region,” said Nikita Punia, executive director of Pharmasyntez Group of Companies.
Pharmasyntez-Nord is an advanced pharmaceutical research and production complex, which is a part of the esteemed Pharmasyntez group of companies. It specializes in the cutting-edge development and manufacturing of highly effective medications for the treatment of cancer, autoimmune diseases, and endocrine system disorders. Currently, Pharmasyntez-Nord produces 45 trade names of oncological drugs, 99% of which are included in the list of vital and essential drugs of the Russian Ministry of Health.
Pharmasyntez-Nord’s production capacity for antitumor drugs is 4 million syringes, 10 million vials of liquid and sterile forms, 2.5 million lyophilisates and 100 million tablets per year. Today, antitumor drugs produced by Pharmasyntez Group of Companies are exported to the CIS countries.
